Cogstate's Inflection: Record Signings, AI Automation, and a Shift Beyond Alzheimer's
A landmark year, but not the finish line
Cogstate's FY26 results read like the payoff of a five-year pivot. Revenue grew 15% to just under $61 million, EBIT margin hit 25%, and — more tellingly — the company signed “almost $120 million of contracted future revenue as at 30 June 2026” — Bradley O'Connor, CEO and Managing Director · 2026-08-17, up 54% year-on-year in FY27 recognition and with visible acceleration into years two and three. The headline is impressive, but the deeper story is one of composition: the revenue mix is changing, the go-to-market is scaling, and the operating model is about to become materially more automated.
We really think that these FY '26 results adjust the start for our business. We're just really getting started on the expansion into these mood disorders.
That line from CEO Brad O'Connor – delivered in his closing remarks – captures the posture. It's not a victory lap; it's a setup. The company's earlier concentration in Alzheimer's trials was a known boom-and-bust risk. On the February call, O'Connor had been explicit: “we understand that, that degree of concentration just leads to a relative boom and bust cycle.” — Bradley O'Connor, CEO and Managing Director · 2026-02-18 FY26 is the first full-year proof that the diversification strategy works at scale.
Diversification is the growth engine — and it's not just Alzheimer's anymore
The most striking change is the mix of trial starts. The company initiated 90 new trials in FY26, up from 35 a year ago, and nearly half of those were in mood, sleep, and other neurological conditions, with a further third in rare disease. That's the new indication flywheel turning. Rachel Colite, EVP of Clinical Trials, called out “approximately 40% of the value of new sales contracts have been signed in financial year '26 through our channel partnerships” — Rachel Colite, Executive Vice President of Clinical Trials · 2026-08-17 – a testament to the strategic partner model, anchored by the Medidata relationship that began in October 2024.
The breadth is real: central rating grew 31% year-on-year, site management rose 186%, and mood/sleep/other neuro now accounts for 30% of revenue, up from 14%. The company is also leaning into orexin programs and incretin-based therapies for new disorders, tapping into pharma investment that has accelerated since Lilly's $7.8 billion acquisition of Centessa. The result is a revenue profile that is both more resilient and more predictable, with long-tail visibility into Phase II trials that will mature into Phase III revenue.
The technology flywheel and the margin question
If diversification is the growth story, automation is the margin story. The company has been building AI-enabled tools for years – central monitoring and rater training are now fully developed – and the next phase is broader operational automation. CFO Darren Watson described a two-year build-out of an AI operations-based tool for workflow automation and orchestration, designed to limit head-count growth as trial volume scales. O'Connor is clear about the ambition: “We're investing really purposefully in technology AI-enabled workflows that are accelerating the development of a technology-driven operating system.” — Bradley O'Connor, CEO and Managing Director · 2026-08-17
The margin path is visible in the H2 numbers: gross margin improved to 62% from 53% H1, and EBIT margin jumped to 30%. Management expects to maintain a ~30% EBITDA margin in FY27 despite the investment, and to push gross margins beyond the traditional 58–60% range as automation kicks in. There's a nuance, though: FY26 carry of a favorable FX hedge – Darren Watson and team hedged after the U.S. Liberation Day tariff announcement, when the Aussie dollar fell – gave a small boost to EBITDA. O'Connor acknowledged that: “we did benefit from Darren and the finance team did a great job of taking advantage of the of the U.S. Liberation Day tariff announcement.” — Bradley O'Connor, CEO and Managing Director · 2026-08-17 Without that, maintaining margins requires the automation to deliver.
The company is also returning capital: second annual dividend of 4 cents (up from 2 cents), payout ratio 40%, and an opportunistic buyback remains open. The balance sheet is clean – ~$35 million cash, no debt – which funds both the AI build-out and any bolt-on M&A that might surface.
What's changed? Everything that matters
For investors who've watched Cogstate for years, the FY26 report is a definitive step-change. The prior worry – concentration in Alzheimer's and dependence on a few large pharma sponsors – has been replaced by a diversified, partner-driven pipeline. The 2025 call had already hinted at the Medidata traction: “we are starting to see a number of awards coming through to win and as well as a number of high probability pipeline opportunities.” — Rachel Colite, Executive or Senior Manager (likely in Business Development or Partnerships) · 2025-08-22 That promise has now materialized in the numbers.
The next chapters are about operational leverage and the ability to convert the record book of contracted revenue into sustainable double-digit growth without an offsetting head-count explosion. The AI automation push is the key variable to watch – if it works, Cogstate could deliver the kind of margin expansion that turns a niche CNS-services provider into a high-margin software-like compounder. If it slips, the leverage story may take longer to play out. Either way, FY26 has reset the base.